

Cath Lab Digest

A product, news & clinical update for the cardiac catheterization laboratory specialist

www.cathlabdigest.com • January/February 2026 • vol. 34, no. 1



CATH LAB SPOTLIGHT

Jersey Shore University Medical Center

Margaret McGowan, MSN, RN, CEN, CV-BC, and Tresy Thomas, MSN, RN, FNP-BC

Tell us about your hospital.

Jersey Shore University Medical Center (JSUMC), located in Neptune, New Jersey, offers advanced, compassionate care just minutes from the beach. Serving the communities of central New Jersey, our 691-bed academic medical center is a member of Hackensack Meridian Health and is nationally recognized for nursing excellence with Magnet designation since 1995. We provide numerous advanced specialty care services to a large population, including Level I adult and pediatric trauma services, comprehensive stroke care, cardiac rehabilitation, cancer treatment, structural heart services, cardiothoracic surgery, and much more.

continued on page 16

CLINICAL TRIAL UPDATE

The SELUTION4ISR Clinical Trial

CLD talks with Donald E. Cutlip, MD.

PAGE 8



GUIDEWIRES

The New Stedi Extra Support Guidewire, Designed for Use in TAVR

CLD talks with Tanvir K. Bajwa, MD, FACC, FSCAI.

PAGE 11



CASE REPORT

Eventration of the Diaphragm Presenting as Unstable Angina: The Importance of Looking at Non-Cardiac Findings on Catheterization Cines

Saiyeda S. Ali, MD; Greeshma Molugu, MD; Ruben Abreu, MD; Asad Rizvi, MD; Mehdi Khalafi, MD



PAGE 12

The New Stedi Extra Support Guidewire, Designed for Use in TAVR

CLD talks with Tanvir K. Bajwa, MD, FACC, FSCAI.

Can you share some info about your experience with Evolut and your TAVR program?

I am the Cardiology Director of the Structural Heart Program at Advocate Health St. Luke's Medical Center in Milwaukee, Wisconsin. Our program has been involved in all of the CoreValve/Evolut trials for evaluation of high, intermediate, and low-risk patient populations. Our program treats approximately 700 transcatheter aortic valve replacement (TAVR) patients a year and has implanted over 4,000 Evolut (Medtronic) TAVRs.

What aspects specific to Evolut valve delivery or deployment require extra attention from operators, or have proven to be challenging?

The Evolut valve delivery is reproducible when the cusp overlap and commissural alignment best practices are followed. Utilizing the steps of flush port at 3 o'clock, using the cusp overlap angle for deployment after ensuring the hat marker is at center-front for commissural alignment, and aiming for 3 mm depth makes challenging cases more predictable.

Can you describe the new Stedi Extra Support Guidewire design? How will it help during the TAVR procedure?

The Evolut FX delivery system has a single spine and coupled with the Stedi guidewire (Medtronic), provides a synergy that allows for more predictability with tracking throughout the aorta, and provides stability and predictability for deployment depth and coaxiality.

I am the Cardiology Director of the Structural Heart Program at Advocate Health St. Luke's Medical Center in Milwaukee, Wisconsin. Our program treats approximately 700 transcatheter aortic valve replacement (TAVR) patients a year and has implanted over 4,000 Evolut (Medtronic) TAVRs.

Medtronic has a strong focus on procedure simplification and the Stedi wire contributes significantly to this goal.

What is cusp overlap technique and how does it benefit from the Stedi guidewire?

Cusp overlap technique isolates the non-coronary cusp of the aortic valve, which is the lowest cusp of the valve to achieve our target implant depth. The depth of deployment on the non-coronary cusp decreases the pacemaker rate, based on Medtronic Optimize PRO study data. The Stedi guidewire helps to achieve ideal placement of the delivery system and ultimately the valve between the non-coronary cusp and right coronary cusp commissure, which helps to achieve appropriate depth of valve implant and in turn, decreases pacemaker rates.

It's early in use, but can you describe patient outcomes in procedures where the Stedi wire was used?

The unique design of the Stedi with the softness of the distal curve makes the ventricular component of the wire safe, despite its stiff main body. The main body support has helped us to achieve predictable deployments that are coaxial due to the way that the wire stays positioned during the Evolut deployment. Additionally, the design of the Stedi has allowed us to switch to utilizing only 1 wire per TAVR case, therefore saving money by cutting down on supply usage.





Figure. The Stedi Extra Support Guidewire (Medtronic).

How was incorporating the Stedi into procedures for the TAVR team? What training was required?

We had a brief team in-service by the Medtronic team.

What patient anatomies or procedural situations might be appropriate for the Stedi wire?

I am currently utilizing it for all of my TAVR implants with all valve brands. I think that it is particularly impactful for 34 Evolut Valves and transcatheter aortic valve-in-surgical aortic valve (TAV in SAV) cases due to the stability that it provides. I also feel that could be impactful in mitral cases. ■



Tanvir K. Bajwa, MD, FACC, FSCAI
Cardiology Director, Structural Heart Program, Advocate Health St. Luke's Medical Center, Milwaukee, Wisconsin

A disclosure statement is available with the interview online.

Dr. Tanvir K. Bajwa can be contacted at tanvir.bajwa@aah.org.

